PMID- 34619433
OWN - NLM
STAT- MEDLINE
DCOM- 20211129
LR  - 20211129
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 110
DP  - 2021 Nov
TI  - Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem 
      cell transplantation is an effective treatment modality for multi-hit multiple 
      myeloma.
PG  - 106710
LID - S0145-2126(21)01711-2 [pii]
LID - 10.1016/j.leukres.2021.106710 [doi]
AB  - In order to investigate the efficacy of lenalidomide, bortezomib and 
      dexamethasone (VRD) induction chemotherapy regimen combined with tandem 
      autologous stem cell transplantation (ASCT) in treating multi-hit multiple 
      myeloma (MM), we analyzed 252 cases of newly diagnosed MM treated with the 
      bortezomib-containing induction chemotherapy from June 2016 to June 2019. 
      According to the fluorescence in situ hybridization (FISH) results on diagnosis, 
      the patients were divided into multi-hit MM group (47 cases), single-hit MM group 
      (81 cases), and standard-risk group (124 cases). Our analysis showed that R-ISS 
      stageⅢ in transplantation group and R-ISS stageⅢ, multi-hit and VGPR or above was 
      not achieved at the fourth cycle of chemotherapy in non-transplantation group 
      were independent factors for poor prognosis by univariate and multivariate 
      analyses. Moreover, the overall response rate (ORR) of VRD induction chemotherapy 
      group was significantly higher than that of the non-VRD group in the single-hit 
      and multi-hit groups (P = 0.021, P = 0.032); In terms of ASCT, tandem-ASCT can 
      significantly improve the 2-year PFS (77.8 +/- 3.9 %) and OS (83.3 +/- 5.6 %) of 
      multi-hit MM (P = 0.024, P = 0.037), while single-ASCT only has a limited effect 
      on PFS (61.5 +/- 3.0 %) and OS (71.9 +/- 4.5 %) (P = 0.115, P = 0.155).
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Tang, Shanhao
AU  - Tang S
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China.
FAU - Lu, Yin
AU  - Lu Y
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China.
FAU - Zhang, Pisheng
AU  - Zhang P
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China.
FAU - Chen, Dong
AU  - Chen D
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China.
FAU - Liu, Xuhui
AU  - Liu X
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China.
FAU - Du, Xiaohong
AU  - Du X
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China.
FAU - Cao, Junjie
AU  - Cao J
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China.
FAU - Ye, Peipei
AU  - Ye P
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China.
FAU - Chen, Lieguang
AU  - Chen L
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China.
FAU - Li, Shuangyue
AU  - Li S
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China.
FAU - Sha, Keya
AU  - Sha K
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China.
FAU - Zhuang, Xian Xu
AU  - Zhuang XX
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China.
FAU - Xie, Yiyu
AU  - Xie Y
AD  - Department of Hematology, the First Affiliated Hospital of Soochow University, 
      Suzhou, 215006, China; Yale New Haven Health/Bridgeport Hospital, Bridgeport, 
      06610, USA.
FAU - Wu, Xiaojin
AU  - Wu X
AD  - Department of Hematology, the First Affiliated Hospital of Soochow University, 
      Suzhou, 215006, China. Electronic address: wuxiaojin@suda.edu.cn.
FAU - Pei, Renzhi
AU  - Pei R
AD  - Department of Hematology, the Affiliated People's Hospital of Ningbo University, 
      Ningbo, 315040, China. Electronic address: peirz@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210921
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 69G8BD63PP (Bortezomib)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bortezomib/administration & dosage
MH  - Combined Modality Therapy
MH  - Dexamethasone/administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Hematopoietic Stem Cell Transplantation/*mortality
MH  - Humans
MH  - Induction Chemotherapy/*mortality
MH  - Lenalidomide/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/pathology/*therapy
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Transplantation, Autologous
OTO - NOTNLM
OT  - Autologous stem cell transplantation
OT  - Lenalidomide
OT  - Multi-hit
OT  - Multiple myeloma
OT  - Prognosis
EDAT- 2021/10/08 06:00
MHDA- 2021/11/30 06:00
CRDT- 2021/10/07 20:21
PHST- 2021/08/03 00:00 [received]
PHST- 2021/09/04 00:00 [revised]
PHST- 2021/09/19 00:00 [accepted]
PHST- 2021/10/08 06:00 [pubmed]
PHST- 2021/11/30 06:00 [medline]
PHST- 2021/10/07 20:21 [entrez]
AID - S0145-2126(21)01711-2 [pii]
AID - 10.1016/j.leukres.2021.106710 [doi]
PST - ppublish
SO  - Leuk Res. 2021 Nov;110:106710. doi: 10.1016/j.leukres.2021.106710. Epub 2021 Sep 
      21.